SecBot SecBot
SECBOTREPLAY Home › Report › SLN

SLN · Silence Therapeutics announced positive topline Phase 2 SANRECO trial…

Silence Therapeutics plc · 8-K filed Aug 10, 2026 at 07:57 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 10, 2026 at 07:57 ET

Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polycythemia vera (PV). The primary endpoint was met with a significantly higher proportion of clinical responders (88% vs 19% placebo; p<0.0001), and both Q6W and Q12W dosing showed strong efficacy (93.8% and 81.3% response rates, respectively). The company plans to initiate a Phase 3 trial in 1H 2027, supporting divesiran's potential as a best-in-class siRNA therapy for PV.

  • Primary endpoint met: 88% clinical responders for divesiran vs 19% placebo (p<0.0001), placebo-adjusted response rate 69%.
  • Dose groups: 93.8% response at Q6W and 81.3% at Q12W.
  • Key secondary endpoint: mean phlebotomies reduced to 0.2 (divesiran) vs 2.1 (placebo) during weeks 0-36 (p<0.0001).
  • Safety well-tolerated with no new findings; injection site reactions infrequent and self-limiting.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access